

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

98 JAN 26 PM 2:57

Applicant(s): Christine L. Brakel et al. GROUP 280  
 Serial No.: 07/446,235 Group Art Unit: 1803  
 Filed: December 4, 1989 Examiner: Gary L. Kunz  
 For: **MODIFIED NUCLEOTIDE COMPOUND**

Honorable Commissioner of  
 Patents and Trademark  
 Washington, D.C. 20231

Sir:

Transmitted herewith is a response (Amendment Under 37 C.F.R. §1.115) in the above-identified patent application.

The fee\* has been calculated as shown below:

	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA	RATE	ADDITIONAL FEE
Total	51	Minus	51	= 0	x 11	\$ 0
Indep	7	Minus	7	= 0	x 37	\$ 0
( ) First Presentation of Multiple Dependent Claims					+ 115	\$ 0
TOTAL ADDITIONAL FEE -----						\$ 0

\* Small entity status is established in this application by a properly signed declaration submitted herewith.

( X ) Charge Deposit Account No. 05-1135 in the amount of \$ \_\_\_\_

( ) A check in the amount of \$ \_\_\_\_\_ is attached.

( X ) The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 05-1135: any filing fees under 37 C.F.R. §1.16 for the presentation of extra claims and any patent application processing fees under 37 C.F.R. §1.17.

Copies are being provided in triplicate.

**DECEMBER 7, 1992**  
 Date


ENZO THERAPEUTICS, INC.  
 c/o Enzo Biochem, Inc.  
 60 Executive Boulevard  
 Farmingdale, New York 11735  
 Tel. (212) 856-0876

Attorney's Docket No.: **Enz-47**

Respectfully submitted,



Ronald C. Fedus  
 Registration No. 32,567  
 Attorney for Applicant(s)

FIRST CLASS CERTIFICATE	
I hereby certify that this correspondence is being deposited today with the U.S. Postal Service as first class mail in an envelope addressed to: Commissioner of Patents & Trademarks Washington, D.C. 20231	
 Ronald C. Fedus Reg. No. 32,567	12/7/92 Date